HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Compiling Pre-DSHEA Ingredient List Relies On Bridging FDA-Industry Gap

This article was originally published in The Rose Sheet

Executive Summary

"Nobody said these are easy questions, if they were they would have been answered a long time ago," says Steve Tave, director of FDA's Office of Dietary Supplement Programs. Industry stakeholders at a public meeting recommend a reasonable threshold for evidence that verifies a dietary ingredient was available in the US before Congress passed DSHEA.

You may also be interested in...

HBW Executive Decisions: B+L Leadership Changes; CHPA Promotions; ANH Founder’s Larger Role

Bausch + Lomb CEO brings on colleagues from Allergan; American Herbalists Guild executive director receives ABC award; Joseph Betz joins ABC board of trustees; senior management changes in CHPA communications, foundation; ANH founder Ververk takes US helm, too.

NIH Office Of Dietary Supplements Keeps Tabs On What DSHEA Wrought For US Consumers

While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.

AHPA Offers Hard Copy Supporting NAC's Use In Dietary Supplements Pre-DSHEA

American Herbal Products Association submits comments to on CRN and NPA petitions encouraging FDA to grant an industry request to issue a regulation finding NAC is a lawful dietary ingredient.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts